Grants per year
Personal profile
Training Experience
| 2003 | Residency, Royal College of Physicians, Ireland |
| 2009 | Fellowship, University of Texas Health Science Center, San Antonio |
| 2009 | Fellowship, Royal College of Physicians, Ireland |
Education/Academic qualification
PhD, National University of Ireland
… → 2009
MBBChBAO, National University of Ireland
… → 2000
Fingerprint Dive into the research topics where Devalingam Mahalingam is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 9 Similar Profiles
Neoplasms
Medicine & Life Sciences
Apoptosis
Medicine & Life Sciences
Therapeutics
Medicine & Life Sciences
gemcitabine
Medicine & Life Sciences
Prostatic Neoplasms
Medicine & Life Sciences
Safety
Medicine & Life Sciences
TNF-Related Apoptosis-Inducing Ligand Receptors
Medicine & Life Sciences
Colorectal Neoplasms
Medicine & Life Sciences
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Grants 2017 2022
- 11 Active
Prot #19774: A multicenter Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of the combination of rogaratinib and copanlisib in patients with FGFR-positive, local
Bayer HealthCare Pharmaceuticals, Inc.
10/18/18 → 5/19/21
Project: Research project
Research Output 2008 2019
5
Citations
(Scopus)
A phase II, multicenter, single-arm study of mipsagargin (G-202) as a second-line therapy following sorafenib for adult patients with progressive advanced hepatocellular carcinoma
Mahalingam, D., Peguero, J., Cen, P., Arora, S. P., Sarantopoulos, J., Rowe, J., Allgood, V., Tubb, B. & Campos, L., Jun 2019, In : Cancers. 11, 6, 833.Research output: Contribution to journal › Article
Open Access
Hepatocellular Carcinoma
Disease-Free Survival
Disease Progression
Neoplasms
Magnetic Resonance Imaging
1
Citation
(Scopus)
Current state of liver-directed therapies and combinatory approaches with systemic therapy in hepatocellular carcinoma (HCC)
Viveiros, P., Riaz, A., Lewandowski, R. J. & Mahalingam, D., Aug 2019, In : Cancers. 11, 8, 1085.Research output: Contribution to journal › Review article
Open Access
Hepatocellular Carcinoma
Liver
Therapeutics
Protein-Tyrosine Kinases
Immunotherapy
Docetaxel, Oxaliplatin, and 5-Fluorouracil (DOF) in Metastatic and Unresectable Gastric/Gastroesophageal Junction Adenocarcinoma: A Phase II Study with Long-Term Follow-Up
Rosenberg, A. J., Rademaker, A., Hochster, H. S., Ryan, T., Hensing, T., Shankaran, V., Baddi, L., Mahalingam, D., Mulcahy, M. F. & Benson, A. B., Jan 1 2019, In : Oncologist. 24, 8, p. 1039-e642Research output: Contribution to journal › Article
oxaliplatin
docetaxel
Esophagogastric Junction
Fluorouracil
Stomach
1
Citation
(Scopus)
Heightened JNK activation and reduced XIAP levels promote TRAIL and sunitinib-mediated apoptosis in colon cancer models
Mahalingam, D., Carew, J. S., Espitia, C. M., Cool, R. H., Giles, F. J., De Jong, S. & Nawrocki, S. T., Jul 2019, In : Cancers. 11, 7, 895.Research output: Contribution to journal › Article
Open Access
X-Linked Inhibitor of Apoptosis Protein
Colonic Neoplasms
Phosphotransferases
Apoptosis
Neoplasms
2
Citations
(Scopus)
Nivolumab in Metastatic Adrenocortical Carcinoma: Results of a Phase 2 Trial
Carneiro, B. A., Konda, B., Costa, R. B., Costa, R. L. B., Sagar, V., Gursel, D. B., Kirschner, L. S., Chae, Y. K., Abdulkadir, S. A., Rademaker, A., Mahalingam, D., Shah, M. H. & Giles, F. J., Dec 1 2019, In : The Journal of clinical endocrinology and metabolism. 104, 12, p. 6193-6200 8 p.Research output: Contribution to journal › Article
Adrenocortical Carcinoma
Chemotherapy
Mitotane
Drug Therapy
Disease-Free Survival